6
项与 DNA-HIV-PT123 vaccine(National Institute of Allergy & Infectious Diseases) 相关的临床试验A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DNA, and of MF59®- or AS01B-Adjuvanted Clade C Env Protein in Various Combinations, in Healthy, HIV-Uninfected Adult Participants
This study will evaluate the safety and immune response to the DNA-HIV-PT123 vaccine used in combination with one of two protein vaccines (Bivalent Subtype C gp120/MF59 or Bivalent Subtype C gp120/AS01B) in healthy, HIV-uninfected adults.
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DNA and of MF59-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
The purpose of this study is to evaluate the safety and immune response to an HIV clade C DNA vaccine and to an MF59-adjuvanted clade C Env protein in healthy, HIV-uninfected adults.
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
This study will evaluate the safety, tolerability, and immune response to different combinations of two experimental HIV vaccines-the DNA-HIV-PT123 vaccine and the AIDSVAX® B/E vaccine-in healthy adults who are not infected with HIV.
100 项与 DNA-HIV-PT123 vaccine(National Institute of Allergy & Infectious Diseases) 相关的临床结果
100 项与 DNA-HIV-PT123 vaccine(National Institute of Allergy & Infectious Diseases) 相关的转化医学
100 项与 DNA-HIV-PT123 vaccine(National Institute of Allergy & Infectious Diseases) 相关的专利(医药)
100 项与 DNA-HIV-PT123 vaccine(National Institute of Allergy & Infectious Diseases) 相关的药物交易